Clinical Trial Update: A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update for TAK-438 (vonoprazan) assessing prevention of recurrent gastric or duodenal ulcers in long-term NSAID users; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Gastric Ulcer

Drugs mentioned

• TAK-438 (vonoprazan) (vonoprazan)

Snippet

Sponsor: Takeda | Conditions: Gastric Ulcer, Duodenal Ulcer | Phase 3 | Status: COMPLETED